After a few years of strong growth, AstraZeneca’s share price performance has been lacklustre this year, as the focus has shifted to positive developments at other big pharmas. Furthermore, the firm was not able to meet analyst expectations with its recent late-stage readout of a high-potential oncology drug. Nonetheless, the growth prospects remain robust which, along with improving profitability and a healthy balance sheet, make AstraZeneca an attractive investment proposition at the current s ....
